- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
-
Your selected country is
United States
- Change country/language
-
Promotions
-
sk-testpage
-
BD Primer Program
-
BD Discovery 2021
-
Reagents
-
DO NOT PUBLISH
-
Reagentes Com Valor Promocional
-
Lunch Box Giveaway
-
EQCプログラム 外部精度管理 施設間精度管理
-
Backbone Reagents Promo
-
Backbone Reagents Promo
-
Classic Dyes
-
Back to Lab
-
End of Year
-
Tcell Backbone Panel Promotion
-
BD Horizon™ Human T Cell Backbone Panel
-
New Lab Promotion
-
Flash Sale
-
BD Panel Design Program
-
Real Dyes Sample Offer
-
BD’s 50 Years of Innovation Research Instrument Promotion
-
BD FACSLyric™ Flow Cytometers 50th Anniversary Promo
-
BD FACSAria™ Customer Loyalty Promotion
-
FlowJo™ Software Promotion
-
BD® Research Cloud Promotion
-
sk-testpage
-
Custom BD® AbSeq
-
Custom AbSeq FAQ Answer 2
-
Custom AbSeq FAQ Answer 3
-
Custom AbSeq FAQ Answer 4
-
Custom AbSeq FAQ Answer 5
-
Custom AbSeq FAQ Answer 6
-
Custom AbSeq FAQ Answer 7
-
Custom AbSeq FAQ Answer 8
-
Custom AbSeq FAQ Answer 9
-
Custom AbSeq FAQ Answer 10
-
Custom AbSeq FAQ Answer 11
-
Custom AbSeq FAQ Answer 12
-
Custom AbSeq FAQ Answer 13
-
Custom AbSeq FAQ Answer 14
-
Custom AbSeq FAQ Answer 15
-
Custom AbSeq FAQ Answer 16
-
Custom AbSeq FAQ Answer 17
-
Custom AbSeq FAQ Answer 18
-
Custom AbSeq FAQ Answer 19
-
Custom AbSeq FAQ Answer 20
-
Custom AbSeq FAQ Answer 2
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- United States (English)
- Change country/language
Old Browser
Your account has been put on hold due to inactivity. To re-activate, check your account information and make all necessary updates.
Looks like you're visiting us from {{countryName}}.
Would you like to remain on the current country site or be redirected to one based on your location?
live copy GB
Your account has been put on hold due to inactivity. To re-activate, check your account information and make all necessary updates.
High-Dimensional Flow Cytometry in COVID-19 Research
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
The rapid spread of COVID-19 infections all over the world and the need to develop a vaccine has necessitated the understanding of the adaptive immune response to the SARS-CoV-2 virus. There is an urgent requirement to evaluate the response of human T cells to the SARS-CoV-2 virus through the quantification of virus-specific CD4+ and CD8+ T cells. In this article published in Cell, Grifoni et.al used high dimensional flow cytometry to carry out immunophenotyping of PBMC samples taken from patients who had recovered from COVID-19 and unexposed donors. They performed T cell receptor (TCR) dependent activation-induced marker (AIM) assays to identify and quantify SARS-CoV-2-specific CD4+ T cells in recovered COVID-19 patients. To measure SARS-CoV-2-specific CD8+ T cells in the recovered patients, the authors utilized two complementary methodologies, AIM assays and intracellular cytokine staining (ICS). The authors evaluated whether stronger SARS-CoV-2-specific CD4+ T cell responses were associated with higher antibody titers in COVID-19 cases by examining spike protein-specific CD4+ cells. Finally, to evaluate what antigens were targeted by CD4+ and CD8+ T cells, the authors synthesised an overlapping pool of peptides spanning the entire sequence of SARS-CoV-2 and studied epitope reactivity.
The authors report, using multiple experimental, approaches, that SARS-CoV-2-specific CD4+ T cell and antibody responses are observed in 100% of the COVID-19 cases, and CD8+ responses are observed in approx. 70% of them. Interestingly, the authors also detect SARS-CoV-2 reactive CD4+ cells in 40-60% of the unexposed individuals, which they attribute to cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2. The authors propose that mapping T cell specificities reveals valuable targets for incorporation in candidate vaccine development and distinct specificity patterns between COVID-19 cases and unexposed healthy controls.
The article can be accessed in the Cell journal website.
BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. © 2020 BD. All rights reserved.
Products are for Research Use Only. Not for use in diagnostic or therapeutic procedures.
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.